EVERESTIND / NSE / Constr. - Supplies & Fixtures

Everest Industries

INR 352.0523.40 (-3.31%) 1D

Last updated: 2026-06-15T19:55:09.992037+00:00

Price Chart

1Y Price Trend

Open536.7

High750

Low284.9

Close346.7

Volume94,519

Change-190

Change %-35.40%

Key Information

Ticker SymbolEVERESTIND

Current Price352.05

52-Week High750

52-Week Low284.9

Market Cap559.7

Beta1.17

Volume94,519

ISININE295A01018

Day High353.8

Day Low322.5

Open338

Recommendations

Target High748

Target Low287.4

Target Mean0

Target Median0

Risk Metrics

Overall RiskHigh risk

Board Risk47.44

Key Analysis

Overall score, performance score, return rating, defensive, aggressive, and balanced views.

Download app

Projection Analytics

Best-case, base-case, worst-case, and dynamic AI projection views.

Download app

News

Latest stock news

Everest Industries promoter confirms no encumbrance on shares - scanx.trade1 day ago

Market news

Everest Industries promoter confirms no encumbrance on shares scanx.trade

Everest Industries Ltd Technical Momentum Shifts Amid Persistent Downtrend - MarketsMojo4 days ago

Market news

Everest Industries Ltd Technical Momentum Shifts Amid Persistent Downtrend MarketsMojo

Everest Industries Ltd is Rated Strong Sell - Markets Mojo12 days ago

Market news

Everest Industries Ltd is Rated Strong Sell Markets Mojo

Everest Organics Ltd Downgraded to Sell Amid Mixed Financial and Valuation Signals - Markets Mojo13 days ago

Market news

Everest Organics Ltd Downgraded to Sell Amid Mixed Financial and Valuation Signals Markets Mojo

Everest Ind Consolidated March 2026 Net Sales at Rs 327.17 crore, down 27.72% Y-o-Y - Moneycontrol.com14 days ago

Market news

Everest Ind Consolidated March 2026 Net Sales at Rs 327.17 crore, down 27.72% Y-o-Y Moneycontrol.com

Everest Industries Ltd is Rated Strong Sell - Markets Mojo14 days ago

Market news

Everest Industries Ltd is Rated Strong Sell Markets Mojo

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases - The Manila Times14 days ago

Market news

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases The Manila Times

Everest Industries Q4 FY26: Losses Deepen Amid Revenue Decline and Margin Collapse - Markets Mojo17 days ago

Market news

Everest Industries Q4 FY26: Losses Deepen Amid Revenue Decline and Margin Collapse Markets Mojo